TheraCell Announces First Surgical Use Of TheraFuze DBF® Fiber Bullets™ In An Interbody TLIF Cage
TheraCell completes first surgical case with the TheraFuze DBF® Fiber Bullets™ offering surgeons an improved solution for allograft delivery in MIS surgeries
News provided by
Share this article
Share this article
LOS ANGELES, Dec. 30, 2020 /PRNewswire/ TheraCell Inc., a leading allograft solution company, today announced that it has completed the first surgical case using its TheraFuze DBF® Fiber Bullets™. This unique DBF fiber form is designed for minimal access delivery into expandable cages, revisions and other surgical applications.
The lyophilized Fiber Bullets™ can be dispensed using minimally invasive techniques into the desired site, delivering osteoconductive demineralized bone fibers with osteoinductive potential to stimulate new bone formation for long term structural stability.